Summary & Overview
CPT 64643: Neurolytic Destruction of Somatic Nerves
CPT 64643 covers neurolytic destruction of somatic nerves by chemical, thermal, electrical, or radiofrequency methods. This targeted interventional procedure is used in neurology and pain management to reduce intractable pain or muscle overactivity when conservative treatments fail. Nationally, neurolytic procedures are clinically important because they provide a minimally invasive option for selected patients with disabling spasticity or neuropathic pain.
Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage considerations across major commercial and federal payers, typical site-of-service patterns (office-based procedures), and clinical context for utilization. The publication outlines coding relationships to related chemodenervation and electromyography services to aid in clinical documentation and billing alignment.
This summary equips clinicians, coding staff, and administrators with a clear description of the procedure, payer landscape, and topics to expect in the full publication, including reimbursement benchmarks, policy clarifications, and coding guidance. Data not available in the input is noted where applicable.
CPT Code Overview
CPT 64643 describes destruction by neurolytic agent (e.g., chemical, thermal, electrical, or radiofrequency) procedures on the somatic nerves. This procedure is used to interrupt somatic nerve function to relieve refractory pain or spasticity related to neuromuscular conditions. The service falls under the Neurology service type and is most commonly performed in the office (POS 11) setting.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to a neurology or pain medicine clinic for focal, refractory muscle hyperactivity causing pain, functional impairment, or postural deformity (for example, a patient with spasmodic torticollis). The patient undergoes evaluation including history, focused neurologic and musculoskeletal exam, and review of prior conservative therapies. After confirming a target somatic nerve or nerve plexus responsible for the symptomatic muscle group and obtaining informed consent, the procedure is scheduled in the office (POS 11). On the day of service the clinician performs an aseptic technique, identifies the target using anatomic landmarks and optionally electrodiagnostic guidance, and administers a neurolytic agent (chemical, thermal, electrical or radiofrequency) to destroy or denervate the somatic nerve supply to the involved muscles. The patient is monitored for immediate adverse effects, given post-procedure instructions, and scheduled for follow-up to assess efficacy and complications.
Coding Specifications
-
Modifier
50(Bilateral Procedure): Use when the neurolytic procedure is performed bilaterally during the same session and payer guidelines permit bilateral reporting. -
Modifier
LT(Left Side): Use to indicate the procedure was performed on the left side when laterality is required by the payer. -
Modifier
RT(Right Side): Use to indicate the procedure was performed on the right side when laterality is required by the payer. -
Use when the neurolytic procedure is separate and distinct from other services performed on the same day (for example, when another injectable or diagnostic procedure is performed in a different anatomical site) and documentation supports distinctness.